The CEO Joins His CFO at Relmada, Same Day
A few hours after the CFO stepped in, CEO Sergio Traversa put $828,000 into this clinical-stage biotech running a Phase 2 bladder cancer trial. Two C-suite buys in one day at $4.14, with the stock washed out at an RSI of 29 and money flow near 23. That's the cluster you want, and the history here is loud: insider buys on this name have averaged a 40% gain and beaten the market 88% of the time over 30 days. The 90-day record fades hard, so this is a fast trade, not a hold. If you want defined risk, look at bull put spreads under $4.14 and let the wash-out work for you.
The Filing
| Ticker | RLMD |
| Company | RELMADA THERAPEUTICS, INC. |
| Insider | Sergio Traversa, Chief Executive Officer |
| Buy amount | $828,000 |
| Filing date | September 11, 2026 |
| Conviction | Favorable · 68/100 |
| Setup type | Contrarian Setup |
Ultimate members received this analysis in real time.